Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Hangzhou Zhongmei Huadong Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Hangzhou Zhongmei Huadong Pharmaceutical Co (Global / Institutional) sponsors 24 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (10 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)339 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Hangzhou Zhongmei Huadong Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)24
Active Pipeline (Recruiting Now)16 (10)
Completed vs Stopped Early6 / 0 (0.0%)
Median Closed Actual Enrollment339 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Hangzhou Zhongmei Huadong Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Peking University People's HospitalBeijing, Beijing Municipality6
Zhejiang Provincial People's HospitalHangzhou, Zhejiang4
Affiliated Hospital of Jiangsu UniversityZhenjiang, Jiangsu4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07357831A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsPhase IIICOMPLETED
NCT06648772Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 StudyPhase IIICOMPLETED
NCT06481085To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusPhase IICOMPLETED
NCT06631170Efficacy and Safety of Roflumilast Cream in Subjects With Atopic DermatitisPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Hangzhou Zhongmei Huadong Pharmaceutical Co Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI